Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists hunt for autism genes in large blood study

NCT ID NCT07311213

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to collect blood samples from 450 people, including individuals with autism spectrum disorder (ASD), their relatives, and healthy controls. Researchers will isolate cells from the blood to study genetic factors and biological processes linked to autism. The goal is to better understand what causes ASD and identify potential targets for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help identify new genetic causes and biological pathways in autism, potentially pointing toward future therapeutic targets.
What could go wrong
This is an early-stage observational study, not a treatment trial. It may not directly lead to new therapies, and findings may take years to translate into clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2041

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: ● For all participants : * 1\) Be Included in the "Genes and Autism" protocol (C07-33 or C16-89). * 2\) Affiliated to the social insurance, Universal Health Coverage or any equivalent system. →As a Reminder : C07-33 inclusion criteria ● Participants with ASD. * 1\) Autistic patients must meet the diagnostic criteria of DSM-IV \[American Psychiatric Association, 1994\] and the criteria of ADI-R (Autism Diagnostic Interview-Revised, Lord et al., 1994) and ADOS for autism. ..Or.. Patients with Asperger's syndrome must meet the DSM-IV criteria as well as the ASDI criteria for Asperger's syndrome (Asperger Syndrome Diagnostic Interview, Gillberg et al., 2001) and the ADOS for autism spectrum disorders. ..Or.. Patients with ASD must meet diagnostic criteria of DSM-IV and ADOS criteria for autism spectrum disorders * 2\) Be at least 2 years old, with no upper age limit * 3\) Somatic state compatible with blood test ● Adult controls and adult relatives of controls * 1\) Be between 18 and 65 years old * 2\) Somatic and intellectual state compatible with blood test ● Controls with mental retardation * 1\) Minimum age of 2 yearsIQ \< 70Child controls * 2\) Minimum age of 2 years →As a Reminder : inclusion criteria C16-89 ● Probands with ASD * 1\) Meet the diagnostic criteria for ASD of the of DSM-5 \[American Psychiatric Association, 2012\]. The diagnosis will be based on a consensus between the clinical expertise of expert clinicians, the scores of the Autism Diagnostic Interview-Revised (ADI-R) (Lord et al, 2003) and those of the Autism Diagnosis Observational Scale (ADOS-2) (Lord et al, 1994) * 2\) Be at least 24 months old with no upper age limit * 3\) Somatic state compatible with a blood test * 4\) Affiliation to the Social Insurance * 5\) Signature of informed consent by the applicant or by the holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship ● Controls wihout ASD * 1\) At least 24 months old * 2\) Somatic and Intellectual state compatible with a blood test * 3\) Affiliation in the Social Insurance * 4\) Signature of informed consent by the subject or by holders of parental authority if the subject is a minor, or by the guardian if the subject is under guardianship ● Relatives of the probands with ASD or of controls without ASD * 1\) At least 24 months old * 2\) Somatic and intellectual state compatible with blood test * 3\) Affiliation to the Social Insurance * 4\) Signature of informed consent by the subject or by the holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship Exclusion Criteria: * For all participants * 1\) Refusal to have a blood test * 2\) Medical illness (including psychiatric disorder) not yet fully stabilised and making participation in the study impossible * 3\) Person subject to a mesure of lagal protection * 4\) Known serology : VIH+ or VBH+ or VCH+ * As a reminder : exclusion criteria C07-33 * 1\) For all participants : Severe Intelectual Deficiency (IQ,35 or developmental age \<18 months) * 2\) Controls : Neurological or psychiatric history other than mental retardation o Psychiatric history, except for mental retardation, assessed using the DIGS (Diagnostic Interview for Genetic Studies, Nurnberger et al., 1994) for adults or the Kiddie-SADS (Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children, Orvaschel et al., 1982) o History of epileptic episodes o Immunosuppressive treatment or known immunoinflammatory disease →As a reminder : exclusion criteria C16-89 * 1\) Probands with Autism Spectrum Disorder o Severe intellectual disability (IQ\<35 or developmental age \<18 months) * 2\) Controls (neurotypical development) o Identified intellectual disorder or cognitive developmental disorder * Personal psychiatric history of schizophrenia, bipolar disorder, substance use disorders (except tobacco), recurrent depression (\>2 episodes, lifetime), severe unstabilized anxiety disorder * History of epilepsy episodes or severe neurological disease * 3\) Relatives of the TSA applicants or controls * Medical condition (psychiatric or somatic) not compatible with inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Robert Debré

    Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.